Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy-the MecMeth/NOA-24 trial
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: 10.1186/s13063-021-05977-0
- Ereignis
-
Veröffentlichung
- (wo)
-
Aachen
- (wer)
-
Universitätsbibliothek der RWTH Aachen
- (wann)
-
2022
- Urheber
-
Zeyen, Thomas
Potthoff, Anna-Laura
Nemeth, Robert
Heiland, Dieter H.
Burger, Michael C.
Steinbach, Joachim Peter
Hau, Peter
Tabatabai, Ghazaleh
Glas, Martin
Schlegel, Uwe
Grauer, Oliver
Krex, Dietmar
Schnell, Oliver
Goldbrunner, Roland
Sabel, Michael
Thon, Niklas
Delev, Daniel I.
Clusmann, Hans
Seidel, Clemens
Güresir, Erdem
Schmid, Matthias
Schuß, Patrick
Giordano, Frank Anton
Radbruch, Alexander
Becker, Albert
Weller, Johannes
Schaub, Christina
Vatter, Hartmut
Schilling, Judith
Winkler, Frank
Herrlinger, Ulrich
Schneider, Matthias
- DOI
-
10.18154/RWTH-CONV-250416
- URN
-
urn:nbn:de:101:1-2023040206525556024971
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:46 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Zeyen, Thomas
- Potthoff, Anna-Laura
- Nemeth, Robert
- Heiland, Dieter H.
- Burger, Michael C.
- Steinbach, Joachim Peter
- Hau, Peter
- Tabatabai, Ghazaleh
- Glas, Martin
- Schlegel, Uwe
- Grauer, Oliver
- Krex, Dietmar
- Schnell, Oliver
- Goldbrunner, Roland
- Sabel, Michael
- Thon, Niklas
- Delev, Daniel I.
- Clusmann, Hans
- Seidel, Clemens
- Güresir, Erdem
- Schmid, Matthias
- Schuß, Patrick
- Giordano, Frank Anton
- Radbruch, Alexander
- Becker, Albert
- Weller, Johannes
- Schaub, Christina
- Vatter, Hartmut
- Schilling, Judith
- Winkler, Frank
- Herrlinger, Ulrich
- Schneider, Matthias
- Universitätsbibliothek der RWTH Aachen
Entstanden
- 2022
Ähnliche Objekte (12)
Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy—the MecMeth/NOA-24 trial
Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy - the MecMeth/NOA-24 trial
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial
Stanniocalcin-1 promotes temozolomide resistance of glioblastoma through regulation of MGMT
Mitochondria‐Targeted Temozolomide Probe for Overcoming MGMT‐Mediated Resistance in Glioblastoma
A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma
BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression
Fstl1/DIP2A/MGMT signaling pathway plays important roles in temozolomide resistance in glioblastoma
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
Hedgehog/Gli1 signaling pathway regulates MGMT expression and chemoresistance to temozolomide in human glioblastoma
ELEVATE – evaluating Temozolomide and Nivolumab in patients with advanced unresectable previously treated oesophagogastric adenocarcinoma with MGMT methylation: study protocol for a single arm phase II trial
Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy—the MecMeth/NOA-24 trial
Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy - the MecMeth/NOA-24 trial
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial
Stanniocalcin-1 promotes temozolomide resistance of glioblastoma through regulation of MGMT
Mitochondria‐Targeted Temozolomide Probe for Overcoming MGMT‐Mediated Resistance in Glioblastoma
A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma
BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression
Fstl1/DIP2A/MGMT signaling pathway plays important roles in temozolomide resistance in glioblastoma
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
Hedgehog/Gli1 signaling pathway regulates MGMT expression and chemoresistance to temozolomide in human glioblastoma
ELEVATE – evaluating Temozolomide and Nivolumab in patients with advanced unresectable previously treated oesophagogastric adenocarcinoma with MGMT methylation: study protocol for a single arm phase II trial
Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy—the MecMeth/NOA-24 trial
Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy - the MecMeth/NOA-24 trial
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial
Stanniocalcin-1 promotes temozolomide resistance of glioblastoma through regulation of MGMT
Mitochondria‐Targeted Temozolomide Probe for Overcoming MGMT‐Mediated Resistance in Glioblastoma
A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma
BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression
Fstl1/DIP2A/MGMT signaling pathway plays important roles in temozolomide resistance in glioblastoma
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
Hedgehog/Gli1 signaling pathway regulates MGMT expression and chemoresistance to temozolomide in human glioblastoma